Antiviral medications with activity

Antiviral medications with activity against influenza viruses are an important adjunct to influenza vaccine in the control of influenza.

Influenza antiviral prescription drugs can be used to treat influenza or to prevent influenza.
Five licensed prescription influenza antiviral agents are available in the United States.
Three influenza antiviral medications approved by the U.S. Food and Drug Administration (FDA) are recommended for use in the United States during the 2014-2015 influenza season: oral oseltamivir (Tamiflu®), inhaled zanamivir (Relenza®), and intravenous peramivir (Rapivab®). These drugs are chemically related antiviral medications known as neuraminidase inhibitors that have activity against both influenza A and B viruses.
Amantadine and rimantadine are antiviral drugs in a class of medications known as adamantanes. These medications are active against influenza A viruses, but not influenza B viruses. As in recent past seasons, there continues to be high levels of resistance (>99%) to adamantanes among influenza A (H3N2) and influenza A (H1N1) pdm09 ("2009 H1N1") viruses. Therefore, amantadine and rimantadine are not recommended for antiviral treatment or chemoprophylaxis of currently circulating influenza A viruses.
Antiviral resistance to oseltamivir, zanamivir, and peramivir among circulating influenza viruses is currently low, but this can change. Also, antiviral resistance can emerge during or after treatment in some patients (e.g., immunosuppressed).
For information about antiviral drug resistance to influenza viruses and guidance on the use of influenza antiviral medications when antiviral resistance is suspected or documented this season, see Antiviral Drug-Resistance among Influenza Viruses.
For weekly surveillance data on antiviral resistance this season, see the FluView U.S. Influenza Surveillance Report.

ผลลัพธ์ (อังกฤษ) 2:

Antiviral medications with Activity Against influenza viruses are an important Adjunct to influenza Vaccine in The Control of influenza. Influenza Antiviral prescription Drugs Can be Used to Treat influenza or to Prevent influenza. Five Licensed prescription influenza Antiviral Agents are Available in The United States. Three influenza. antiviral medications approved by the US Food and Drug Administration (FDA) are recommended for use in the United States during the 2014-2015 influenza season: oral oseltamivir (Tamiflu®), inhaled zanamivir (Relenza®), and intravenous peramivir (Rapivab®). . These are chemically Related Drugs Antiviral medications Known As neuraminidase inhibitors that Have Both influenza A and B viruses Activity Against. Amantadine and rimantadine are in a class of medications Antiviral Drugs Known As Adamantanes. These medications are active against influenza A viruses, but not influenza B viruses. As in recent past seasons, there continues to be high levels of resistance (> 99%) to adamantanes among influenza A (H3N2) and influenza A (H1N1) pdm09 ("2009 H1N1") viruses. Therefore, amantadine and rimantadine are Not Recommended for Antiviral Treatment or chemoprophylaxis of influenza A viruses currently Circulating. Antiviral resistance to oseltamivir, zanamivir, and Peramivir Circulating Among influenza viruses is currently Low, but this Can Change. Also, Antiviral resistance Can emerge during or After Treatment in some patients (eg, immunosuppressed). For information About Antiviral Drug resistance to influenza viruses and Guidance on The Use of influenza Antiviral medications When Antiviral resistance is suspected or documented this Season, See Antiviral Drug. Among -Resistance Influenza Viruses. For Weekly surveillance Data on Antiviral resistance this Season, See The FluView US Influenza Surveillance Report.

ผลลัพธ์ (อังกฤษ) 3:

Antiviral medications with activity against influenza viruses are an important adjunct to influenza vaccine in the control. Of influenza.

Influenza antiviral prescription drugs can be used to treat influenza or to prevent influenza.
Five licensed. Prescription influenza antiviral agents are available in the United States.
Three influenza antiviral medications approved. By the U.S.Food and Drug Administration (FDA) are recommended for use in the United States during the 2014-2015 influenza season:? Oral oseltamivir (Tamiflu game systems), inhaled zanamivir (Relenza game systems), and intravenous peramivir (Rapivab apertium). These drugs are chemically. Related antiviral medications known as neuraminidase inhibitors that have activity against both influenza A and B viruses.
.Amantadine and rimantadine are antiviral drugs in a class of medications known as adamantanes. These medications are active. Against influenza, A viruses but not influenza B viruses. As in recent past seasons there continues, to be high levels of. Resistance (> 99%) to adamantanes among influenza A (H3N2) and influenza A (H1N1) pdm09 ("2009 H1N1."), Therefore viruses.Amantadine and rimantadine are not recommended for antiviral treatment or chemoprophylaxis of currently circulating influenza. A viruses.
Antiviral resistance, to oseltamivir zanamivir and peramivir, among circulating influenza viruses is currently. Low but this, can change. Also antiviral resistance, can emerge during or after treatment in some patients (e.g, immunosuppressed).
.For information about antiviral drug resistance to influenza viruses and guidance on the use of influenza antiviral medications. When antiviral resistance is suspected or documented this season see Antiviral, Drug-Resistance among Influenza Viruses.
For. Weekly surveillance data on antiviral resistance, this season see the FluView U.S. Influenza Surveillance Report.